The upgrade from In-Line to Outperform by Evercore ISI Group analyst Umer Raffat indicates a positive outlook for Teva Pharmaceutical Indus (NYSE:TEVA) in the short term. This is likely to have a positive impact on the stock price as investors may see this as a signal to buy or hold the stock.